



ASX ANNOUNCEMENT

Starpharma signs Priostar[®] Agrochemical Partnership with Gowan

Melbourne, Australia and Yuma, Arizona; 16 September 2013: Starpharma Holdings Ltd (ASX:SPL; OTCQX: SPHRY) and Gowan Company LLC today announced a new partnership using Starpharma's Priostar[®] dendrimer technology in crop protection formulations.

Under the agreement, Starpharma's Priostar[®] dendrimers will be evaluated as potential enhancements for certain Gowan products intended for high value markets.

The partnership with Gowan, a US-based company with global agrochemical sales of more than US\$300 million, aims to broaden crop protection offerings and open new markets through the use of Starpharma's Priostar[®] dendrimer technology.

"We are excited at the prospect of working with Gowan to develop new formulation options using our Priostar[®] dendrimers for high value markets," said Starpharma Chief Executive Officer Dr. Jackie Fairley. "Gowan's focus on providing tailored solutions to farmers' problems fits well with our technology's capabilities."

"At Gowan we are proud of our history of providing a complete offering to farmers and we are very pleased to be able to include Starpharma's innovative technology for potential improvements to our crop protection formulations," said Sandra Alcaraz, Disruptive Technologies Manager.

"With a strong product portfolio and international distribution network, we are able to effectively apply innovative technologies in crop protection products for our key markets."

The benefits of Starpharma's Priostar[®] dendrimers to agrochemical companies and end-user growers can include:

- Improved product efficacy;
- More concentrated formulations to reduce supply chain costs and for greater ease of handling;
- Reduction in solvent loading; and
- Improved bioavailability through increased adhesion, to reduce losses due to rain run-off, and the need for multiple applications.

Starpharma continues to advance the commercialisation of Priostar[®] for crop protection applications via both an internal research program and through valued partnerships with other crop protection companies.

ABOUT GOWAN COMPANY

Gowan Company LLC, based in Yuma, Arizona, USA, is a family-owned registrant and marketer of crop protection solutions for specialty crops and niche markets of agriculture. Our products include insecticides/miticides, fungicides, and herbicides. Our critical competencies are field sales and development, pesticide registration, formulation and efficient market delivery.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca. In its internal program Starpharma has announced significant tumour-targeting results in its docetaxel (Taxotere®) program, with animal studies showing its dendrimer-enhanced version of docetaxel to have significantly superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals Starpharma has a series of partnerships with leading industry players including Nufarm (ASX:NUF) and Makhteshim Agan as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

FOR FURTHER INFORMATION

Media:

Buchan Consulting

Rebecca Wilson

Mob: +61 417 382 391

rwilson@buchanwe.com.au

Danny Rose

Mob: +61 407 25 00 88

drose@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer
+61 3 8532 2704

Ben Rogers, Company Secretary
ben.rogers@starpharma.com

www.starpharma.com

Gowan Company:

Sandra Alcaraz
Disruptive Technologies and IP Manager
(928) 819-1596
salcaraz@gowanco.com

<http://www.gowanco.com>

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.